uniQure announces additional Phase I/II data for AMT-130 in Huntington’s

uniQure (QURE) said additional data from ongoing Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease show continued slowing of disease progression.